Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases

Autoimmunity

Volumn 39, Issue 5, 2006, Pages 417-428

  Fischetti, Fabio ^a   Tedesco, Francesco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Complement components; Complement regulators; Endothelial cells; Inflammation; Vasculitis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 10A; C REACTIVE PROTEIN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C7; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RANTES; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; BLOOD CLOTTING; CELL STIMULATION; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; DIABETIC ANGIOPATHY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SYSTEMIC VASCULITIS; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; THROMBOSIS; VASCULITIS;

EID: 33747681533     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600739712     Document Type: Review

References (163)

1. Morris, KM and Aden, DP and Knowles, BB and Colten, HR. (1982) Complement biosynthesis by the human hepatoma-derived cell line HepG2 J Clin Invest, 70, pp. 906-913.
2. Johnson, E and Hetland, G. (1988) Mononuclear phagocytes have the potential to synthesize the complete functional complement system Scand J Immunol, 27, pp. 489-493.
3. Garred, P and Hetland, G and Mollnes, TE and Stoervold, G. (1990) Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts Scand J Immunol, 32, pp. 555-560.
4. Montinaro, V and Serra, L and Perissutti, S and Ranieri, E and Tedesco, F and Schena, FP. (1995) Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines Kidney Int, 47, pp. 829-836.
5. Gasque, P and Fontaine, M and Morgan, BP. (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines J Immunol, 154, pp. 4726-4733.
6. Bernfield, M and Gotte, M and Park, PW and Reizes, O and Fitzgerald, ML and Lincecum, J and Zako, M. (1999) Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem, 68, pp. 729-777.
7. Esmon, CT. (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation J Biol Chem, 264, pp. 4743-4746.
8. Broze, GJ, Jr. (1995) Tissue factor pathway inhibitor Thromb Haemost, 74, pp. 90-93.
9. Levin, EG and Marotti, KR and Santell, L. (1989) Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA J Biol Chem, 264, pp. 16030-16036.
10. Palmer, RM and Ferrige, AG and Moncada, S. (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor Nature, 327, pp. 524-526.
11. Cines, DB and Pollak, ES and Buck, CA and Loscalzo, J and Zimmerman, GA and McEver, RP and Pober, JS and Wick, TM and Konkle, BA and Schwartz, BS and Barnathan, ES and McCrae, KR and Hug, BA and Schmidt, AM and Stern, DM. (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders Blood, 91, pp. 3527-3561.
12. Gulati, P and Lemercier, C and Guc, D and Lappin, D and Whaley, K. (1993) Regulation of the synthesis of C1 subcomponents and C1-inhibitor Behring Inst Mitt, pp. 196-203.
13. Gulati, P and Guc, D and Lemercier, C and Lappin, D and Whaley, K. (1994) Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium Rheumatol Int, 14, pp. 13-19.
14. Warren, HB and Pantazis, P and Davies, PF. (1987) The third component of complement is transcribed and secreted by cultured human endothelial cells Am J Pathol, 129, pp. 9-13.
15. Dauchel, H and Julen, N and Lemercier, C and Daveau, M and Ozanne, D and Fontaine, M and Ripoche, J. (1990) Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids Eur J Immunol, 20, pp. 1669-1675.
16. Langeggen, H and Pausa, M and Johnson, E and Casarsa, C and Tedesco, F. (2000) The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system Clin Exp Immunol, 121, pp. 69-76.
17. Wurzner, R and Joysey, VC and Lachmann, PJ. (1994) Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7 J Immunol, 152, pp. 4624-4629.
18. Johnson, E and Hetland, G. (1991) Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro Scand J Immunol, 33, pp. 667-671.
19. Langeggen, H and Berge, KE and Macor, P and Fischetti, F and Tedesco, F and Hetland, G and Berg, K and Johnson, E. (2001) Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro Apmis, 109, pp. 73-78.
20. Brooimans, RA and van der Ark, AA and Buurman, WA and van Es, LA and Daha, MR. (1990) Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1 J Immunol, 144, pp. 3835-3840.
21. Berge, V and Johnson, E and Berge, KE. (1996) Interleukin-1 alpha, interleukin 6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro Apmis, 104, pp. 213-219.
22. Ueki, A and Sai, T and Oka, H and Tabata, M and Hosokawa, K and Mochizuki, Y. (1987) Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro Immunology, 61, pp. 11-14.
23. Vakeva, A and Meri, S. (1998) Complement activation and regulator expression after anoxic injury of human endothelial cells Apmis, 106, pp. 1149-1156.
24. Sheerin, NS and Zhou, W and Adler, S and Sacks, SH. (1997) TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells Kidney Int, 51, pp. 703-710.
25. Vastag, M and Skopal, J and Kramer, J and Kolev, K and Voko, Z and Csonka, E and Machovich, R and Nagy, Z. (1998) Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4 Immunobiology, 199, pp. 5-13.
26. Ripoche, J and Mitchell, JA and Erdei, A and Madin, C and Moffatt, B and Mokoena, T and Gordon, S and Sim, RB. (1988) Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture J Exp Med, 168, pp. 1917-1922.
27. Coulpier, M and Andreev, S and Lemercier, C and Dauchel, H and Lees, O and Fontaine, M and Ripoche, J. (1995) Activation of the endothelium by IL-1 alpha and glucocorticoids results in major increase of complement C3 and factor B production and generation of C3a Clin Exp Immunol, 101, pp. 142-149.
28. Collard, CD and Vakeva, A and Bukusoglu, C and Zund, G and Sperati, CJ and Colgan, SP and Stahl, GL. (1997) Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway Circulation, 96, pp. 326-333.
29. Collard, CD and Vakeva, A and Morrissey, MA and Agah, A and Rollins, SA and Reenstra, WR and Buras, JA and Meri, S and Stahl, GL. (2000) Complement activation after oxidative stress: Role of the lectin complement pathway Am J Pathol, 156, pp. 1549-1556.
30. Fleming, SD and Egan, RP and Chai, C and Girardi, G and Holers, VM and Salmon, J and Monestier, M and Tsokos, GC. (2004) Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice J Immunol, 173, pp. 7055-7061.
31. Mold, C and Morris, CA. (2001) Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation Immunology, 102, pp. 359-364.
32. Volanakis, JE. (2001) Human C-reactive protein: Expression, structure, and function Mol Immunol, 38, pp. 189-197.
33. Nauta, AJ and Bottazzi, B and Mantovani, A and Salvatori, G and Kishore, U and Schwaeble, WJ and Gingras, AR and Tzima, S and Vivanco, F and Egido, J and Tijsma, O and Hack, EC and Daha, MR and Roos, A. (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q Eur J Immunol, 33, pp. 465-473.
34. Navratil, JS and Watkins, SC and Wisnieski, JJ and Ahearn, JM. (2001) The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells J Immunol, 166, pp. 3231-3239.
35. Lozada, C and Levin, RI and Huie, M and Hirschhorn, R and Naime, D and Whitlow, M and Recht, PA and Golden, B and Cronstein, BN. (1995) Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1 Proc Natl Acad Sci USA, 92, pp. 8378-8382.
36. Foreman, KE and Vaporciyan, AA and Bonish, BK and Jones, ML and Johnson, KJ and Glovsky, MM and Eddy, SM and Ward, PA. (1994) C5a-induced expression of P-selectin in endothelial cells J Clin Invest, 94, pp. 1147-1155.
37. Albrecht, EA and Chinnaiyan, AM and Varambally, S and Kumar-Sinha, C and Barrette, TR and Sarma, JV and Ward, PA. (2004) C5a-induced gene expression in human umbilical vein endothelial cells Am J Pathol, 164, pp. 849-859.
38. Kilgore, KS and Shen, JP and Miller, BF and Ward, PA and Warren, JS. (1995) Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1 J Immunol, 155, pp. 1434-1441.
39. Hattori, R and Hamilton, KK and McEver, RP and Sims, PJ. (1989) Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface J Biol Chem, 264, pp. 9053-9060.
40. Tedesco, F and Pausa, M and Nardon, E and Introna, M and Mantovani, A and Dobrina, A. (1997) The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity J Exp Med, 185, pp. 1619-1627.
41. Dobrina, A and Pausa, M and Fischetti, F and Bulla, R and Vecile, E and Ferrero, E and Mantovani, A and Tedesco, F. (2002) Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo Blood, 99, pp. 185-192.
42. Casarsa, C and De Luigi, A and Pausa, M and De Simoni, MG and Tedesco, F. (2003) Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain Eur J Immunol, 33, pp. 1260-1270.
43. van den Berg, RH and Faber-Krol, MC and Sim, RB and Daha, MR. (1998) The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells J Immunol, 161, pp. 6924-6930.
44. Czermak, BJ and Sarma, V and Bless, NM and Schmal, H and Friedl, HP and Ward, PA. (1999) In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha J Immunol, 162, pp. 2321-2325.
45. Kilgore, KS and Flory, CM and Miller, BF and Evans, VM and Warren, JS. (1996) The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells Am J Pathol, 149, pp. 953-961.
46. Kilgore, KS and Schmid, E and Shanley, TP and Flory, CM and Maheswari, V and Tramontini, NL and Cohen, H and Ward, PA and Friedl, HP and Warren, JS. (1997) Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation Am J Pathol, 150, pp. 2019-2031.
47. Halperin, JA and Taratuska, A and Nicholson-Weller, A. (1993) Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells J Clin Invest, 91, pp. 1974-1978.
48. Benzaquen, LR and Nicholson-Weller, A and Halperin, JA. (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells J Exp Med, 179, pp. 985-992.
49. Selvan, RS and Kapadia, HB and Platt, JL. (1998) Complement-induced expression of chemokine genes in endothelium: Regulation by IL-1-dependent and -independent mechanisms J Immunol, 161, pp. 4388-4395.
50. Platt, JL and Dalmasso, AP and Lindman, BJ and Ihrcke, NS and Bach, FH. (1991) The role of C5a and antibody in the release of heparan sulfate from endothelial cells Eur J Immunol, 21, pp. 2887-2890.
51. Ikeda, K and Nagasawa, K and Horiuchi, T and Tsuru, T and Nishizaka, H and Niho, Y. (1997) C5a induces tissue factor activity on endothelial cells Thromb Haemost, 77, pp. 394-398.
52. Christiansen, VJ and Sims, PJ and Hamilton, KK. (1997) Complement C5b-9 increases plasminogen binding and activation on human endothelial cells Arterioscler Thromb Vasc Biol, 17, pp. 164-171.
53. Hamilton, KK and Ji, Z and Rollins, S and Stewart, BH and Sims, PJ. (1990) Regulatory control of the terminal complement proteins at the surface of human endothelial cells: Neutralization of a C5b-9 inhibitor by antibody to CD59 Blood, 76, pp. 2572-2577.
54. Lupia, E and Del Sorbo, L and Bergerone, S and Emanuelli, G and Camussi, G and Montrucchio, G. (2003) The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils Immunology, 109, pp. 557-563.
55. Peerschke, EI and Malhotra, R and Ghebrehiwet, B and Reid, KB and Willis, AC and Sim, RB. (1993) Isolation of a human endothelial cell C1q receptor (C1qR) J Leukoc Biol, 53, pp. 179-184.
56. Peerschke, EI and Smyth, SS and Teng, EI and Dalzell, M and Ghebrehiwet, B. (1996) Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q J Immunol, 157, pp. 4154-4158.
57. Malhotra, R and Willis, AC and Jensenius, JC and Jackson, J and Sim, RB. (1993) Structure and homology of human C1q receptor (collectin receptor) Immunology 78, pp. 341-348.
58. Malhotra, R and Thiel, S and Reid, KB and Sim, RB. (1990) Human leukocyte C1q receptor binds other soluble proteins with collagen domains J Exp Med, 172, pp. 955-959.
59. Ghebrehiwet, B and Silvestri, L and McDevitt, C. (1984) Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization J Exp Med, 160, pp. 1375-1389.
60. Ghebrehiwet, B and Lim, BL and Peerschke, EI and Willis, AC and Reid, KB. (1994) Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q J Exp Med, 179, pp. 1809-1821.
61. Feng, X and Tonnesen, MG and Peerschke, EI and Ghebrehiwet, B. (2002) Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading J Immunol, 168, pp. 2441-2448.
62. Ogden, CA and deCathelineau, A and Hoffmann, PR and Bratton, D and Ghebrehiwet, B and Fadok, VA and Henson, PM. (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells J Exp Med, 194, pp. 781-795.
63. Van Beek, J and Bernaudin, M and Petit, E and Gasque, P and Nouvelot, A and MacKenzie, ET and Fontaine, M. (2000) Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse Exp Neurol, 161, pp. 373-382.
64. Monsinjon, T and Gasque, P and Chan, P and Ischenko, A and Brady, JJ and Fontaine, MC. (2003) Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells FASEB J 17, pp. 1003-1014.
65. Schraufstatter, IU and Trieu, K and Sikora, L and Sriramarao, P and DiScipio, R. (2002) Complement c3a and c5a induce different signal transduction cascades in endothelial cells J Immunol, 169, pp. 2102-2110.
66. Haviland, DL and McCoy, RL and Whitehead, WT and Akama, H and Molmenti, EP and Brown, A and Haviland, JC and Parks, WC and Perlmutter, DH and Wetsel, RA. (1995) Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung J Immunol, 154, pp. 1861-1869.
67. Gasque, P and Chan, P and Fontaine, M and Ischenko, A and Lamacz, M and Gotze, O and Morgan, BP. (1995) Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes J Immunol, 155, pp. 4882-4889.
68. Zwirner, J and Fayyazi, A and Gotze, O. (1999) Expression of the anaphylatoxin C5a receptor in non-myeloid cells Mol Immunol, 36, pp. 877-884.
69. Laudes, IJ and Chu, JC and Huber-Lang, M and Guo, RF and Riedemann, NC and Sarma, JV and Mahdi, F and Murphy, HS and Speyer, C and Lu, KT and Lambris, JD and Zetoune, FS and Ward, PA. (2002) Expression and function of C5a receptor in mouse microvascular endothelial cells J Immunol, 169, pp. 5962-5970.
70. Rollins, TE and Siciliano, S and Kobayashi, S and Cianciarulo, DN and Bonilla-Argudo, V and Collier, K and Springer, MS. (1991) Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex Proc Natl Acad Sci USA, 88, pp. 971-975.
71. Norgauer, J and Dobos, G and Kownatzki, E and Dahinden, C and Burger, R and Kupper, R and Gierschik, P. (1993) Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein Eur J Biochem, 217, pp. 289-294.
72. Lucchesi, BR and Kilgore, KS. (1997) Complement inhibitors in myocardial ischemia/reperfusion injury Immunopharmacology, 38, pp. 27-42.
73. Mugge, A and Lopez, JA and Heistad, DD and Lichtlen, PR. (1993) Vasoconstriction in response to activated leukocytes: Implications for vasospasm Eur Heart J, 14(Suppl I), pp. 87-92.
74. Fischetti, F and Carretta, R and Borotto, G and Durigutto, P and Bulla, R and Meroni, PL and Tedesco, F. (2004) Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation Clin Exp Immunol, 135, pp. 186-193.
75. DiScipio, RG and Daffern, PJ and Jagels, MA and Broide, DH and Sriramarao, P. (1999) A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and ransendothelial migration in vitro and in vivo J Immunol, 162, pp. 1127-1136.
76. Bossi, F and Fischetti, F and Pellis, V and Bulla, R and Ferrero, E and Mollnes, TE and Regoli, D and Tedesco, F. (2004) Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex J Immunol, 173, pp. 6921-6927.
77. Saadi, S and Holzknecht, RA and Patte, CP and Stern, DM and Platt, JL. (1995) Complement-mediated regulation of tissue factor activity in endothelium J Exp Med, 182, pp. 1807-1814.
78. Hamilton, KK and Hattori, R and Esmon, CT and Sims, PJ. (1990) Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex J Biol Chem, 265, pp. 3809-3814.
79. Suttorp, N and Seeger, W and Zinsky, S and Bhakdi, S. (1987) Complement complex C5b-8 induces PGI2 formation in cultured endothelial cells Am J Physiol, 253, pp. C13-C21.
80. Bustos, M and Coffman, TM and Saadi, S and Platt, JL. (1997) Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2 J Clin Invest, 100, pp. 1150-1158.
81. Brooimans, RA and Hiemstra, PS and van der Ark, AA and Sim, RB and van Es, LA and Daha, MR. (1989) Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma J Immunol, 142, pp. 2024-2030.
82. Julen, N and Dauchel, H and Lemercier, C and Sim, RB and Fontaine, M and Ripoche, J. (1992) In vitro biosynthesis of complement factor I by human endothelial cells Eur J Immunol, 22, pp. 213-217.
83. Berge, V and Johnson, E and Hogasen, K and Hetland, G. (1992) Human umbilical vein endothelial cells synthesize S-protein (vitronectin) in vitro Scand J Immunol, 36, pp. 119-123.
84. Berge, V and Johnson, E and Hogasen, K. (1997) Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads Apmis, 105, pp. 17-24.
85. Manuelian, T and Hellwage, J and Meri, S and Caprioli, J and Noris, M and Heinen, S and Jozsi, M and Neumann, HP and Remuzzi, G and Zipfel, PF. (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome J Clin Invest, 111, pp. 1181-1190.
86. Asch, AS and Kinoshita, T and Jaffe, EA and Nussenzweig, V. (1986) Decay-accelerating factor is present on cultured human umbilical vein endothelial cells J Exp Med, 163, pp. 221-226.
87. McNearney, T and Ballard, L and Seya, T and Atkinson, JP. (1989) Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells J Clin Invest, 84, pp. 538-545.
88. Mason, JC and Yarwood, H and Sugars, K and Morgan, BP and Davies, KA and Haskard, DO. (1999) Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition Blood, 94, pp. 1673-1682.
89. Mason, JC and Lidington, EA and Yarwood, H and Lublin, DM and Haskard, DO. (2001) Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis Arthritis Rheum, 44, pp. 138-150.
90. Tsuji, S and Kaji, K and Nagasawa, S. (1994) Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface J Immunol, 152, pp. 1404-1410.
91. Lidington, EA and Haskard, DO and Mason, JC. (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury Blood, 96, pp. 2784-2792.
92. Li, SH and Szmitko, PE and Weisel, RD and Wang, CH and Fedak, PW and Li, RK and Mickle, DA and Verma, S. (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells Circulation, 109, pp. 833-836.
93. Venneker, GT and van den Hoogen, FH and Boerbooms, AM and Bos, JD and Asghar, SS. (1994) Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage Lab Invest, 70, pp. 830-835.
94. Morgan, B and Harris, C.(1999) Complement regulatory proteins. London: Academic Press.
95. Langeggen, H and Berge, KE and Johnson, E and Hetland, G. (2002) Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro Inflammation. 26, pp. 103-110.
96. Hindmarsh, EJ and Marks, RM. (1998) Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C Eur J Immunol, 28, pp. 1052-1062.
97. Mason, JC and Lidington, EA and Ahmad, SR and Haskard, DO. (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction Am J Physiol Cell Physiol, 282, pp. C578-C587.
98. Collard, CD and Bukusoglu, C and Agah, A and Colgan, SP and Reenstra, WR and Morgan, BP and Stahl, GL. (1999) Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells Am J Physiol, 276, pp. C450-C458.
99. Noris, M and Remuzzi, G. (2005) Hemolytic uremic syndrome J Am Soc Nephrol, 16, pp. 1035-1050.
100. Thompson, RA and Winterborn, MH. (1981) Hypocomplementaemia due to a genetic deficiency of beta 1H globulin Clin Exp Immunol, 46, pp. 110-119.
101. Hammar, SP and Bloomer, HA and McCloskey, D. (1978) Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3 Am J Clin Pathol, 70, pp. 434-439.
102. Ruiz-Torres, MP and Casiraghi, F and Galbusera, M and Macconi, D and Gastoldi, S and Todeschini, M and Porrati, F and Belotti, D and Pogliani, EM and Noris, M and Remuzzi, G. (2005) Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies Thromb Haemost, 93, pp. 443-452.
103. Ren, G and Hack, BK and Minto, AW and Cunningham, PN and Alexander, JJ and Haas, M and Quigg, RJ. (2002) A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells Clin Immunol, 103, pp. 43-53.
104. Dragon-Durey, MA and Fremeaux-Bacchi, V and Loirat, C and Blouin, J and Niaudet, P and Deschenes, G and Coppo, P and Herman Fridman, W and Weiss, L. (2004) Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases J Am Soc Nephrol, 15, pp. 787-795.
105. Dragon-Durey, MA and Loirat, C and Cloarec, S and Macher, MA and Blouin, J and Nivet, H and Weiss, L and Fridman, WH and Fremeaux-Bacchi, V. (2005) Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome J Am Soc Nephrol, 16, pp. 555-563.
106. Noris, M and Brioschi, S and Caprioli, J and Todeschini, M and Bresin, E and Porrati, F and Gamba, S and Remuzzi, G. (2003) Familial haemolytic uraemic syndrome and an MCP mutation Lancet, 362, pp. 1542-1547.
107. Richards, A and Kemp, EJ and Liszewski, MK and Goodship, JA and Lampe, AK and Decorte, R and Muslumanoglu, MH and Kavukcu, S and Filler, G and Pirson, Y and Wen, LS and Atkinson, JP and Goodship, TH. (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome Proc Natl Acad Sci USA, 100, pp. 12966-12971.
108. Fremeaux-Bacchi, V and Dragon-Durey, MA and Blouin, J and Vigneau, C and Kuypers, D and Boudailliez, B and Loirat, C and Rondeau, E and Fridman, WH. (2004) Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome J Med Genet, 41, pp. e84.
109. Zipfel, PF and Heinen, S and Jozsi, M and Skerka, C. (2006) Complement and diseases: Defective alternative pathway control results in kidney and eye diseases Mol Immunol, 43, pp. 97-106.
110. Hogasen, K and Jansen, JH and Mollnes, TE and Hovdenes, J and Harboe, M. (1995) Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency J Clin Invest, 95, pp. 1054-1061.
111. Pickering, MC and Cook, HT and Warren, J and Bygrave, AE and Moss, J and Walport, MJ and Botto, M. (2002) Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H Nat Genet, 31, pp. 424-428.
112. Acosta, J and Hettinga, J and Fluckiger, R and Krumrei, N and Goldfine, A and Angarita, L and Halperin, J. (2000) Molecular basis for a link between complement and the vascular complications of diabetes Proc Natl Acad Sci USA, 97, pp. 5450-5455.
113. Triolo, G and Giardina, E and Casiglia, D and Scarantino, G and Bompiani, GD. (1991) Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor Clin Exp Immunol, 84, pp. 53-58.
114. Falk, RJ and Sisson, SP and Dalmasso, AP and Kim, Y and Michael, AF and Vernier, RL. (1987) Ultrastructural localization of the membrane attack complex of complement in human renal tissues Am J Kidney Dis, 9, pp. 121-128.
115. Orchard, TJ and Virella, G and Forrest, KY and Evans, RW and Becker, DJ and Lopes-Virella, MF. (1999) Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh epidemiology of diabetes complications study Diabetes, 48, pp. 1454-1458.
116. Accardo-Palumbo, A and Triolo, G and Colonna-Romano, G and Potestio, M and Carbone, M and Ferrante, A and Giardina, E and Caimi, G. (2000) Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells Diabetologia, 43, pp. 1039-1047.
117. Qin, X and Goldfine, A and Krumrei, N and Grubissich, L and Acosta, J and Chorev, M and Hays, AP and Halperin, JA. (2004) Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes Diabetes, 53, pp. 2653-2661.
118. Uesugi, N and Sakata, N and Nangaku, M and Abe, M and Horiuchi, S and Hisano, S and Iwasaki, H. (2004) Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: Glycoxidation-mediated local complement activation Am J Kidney Dis, 44, pp. 224-238.
119. Hughes, GR. (1998) Hughes' syndrome: The antiphospholipid syndrome. A historical view Lupus, 7(Suppl 2), pp. S1-S4.
120. Meroni, PL and Raschi, E and Testoni, C and Tincani, A and Balestrieri, G. (2001) Antiphospholipid antibodies and the endothelium Rheum Dis Clin North Am, 27, pp. 587-602.
121. Pierangeli, SS and Gharavi, AE and Harris, EN. (2000) Experimental thrombosis and antiphospholipid antibodies: New insights J Autoimmun, 15, pp. 241-247.
122. Jankowski, M and Vreys, I and Wittevrongel, C and Boon, D and Vermylen, J and Hoylaerts, MF and Arnout, J. (2003) Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster Blood, 101, pp. 157-162.
123. Fischetti, F and Durigutto, P and Pellis, V and Debeus, A and Macor, P and Bulla, R and Bossi, F and Ziller, F and Sblattero, D and Meroni, P and Tedesco, F. (2005) Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor Blood, 106, pp. 2340-2346.
124. Cervera, R and Asherson, RA and Acevedo, ML and Gomez-Puerta, JA and Espinosa, G and De La Red, G and Gil, V and Ramos-Casals, M and Garcia-Carrasco, M and Ingelmo, M and Font, J. (2004) Antiphospholipid syndrome associated with infections: Clinical and microbiological characteristics of 100 patients Ann Rheum Dis, 63, pp. 1312-1317.
125. Asherson, RA and Cervera, R. (2003) Catastrophic antiphospholipid syndrome Curr Rheumatol Rep, 5, pp. 395-400.
126. Pierangeli, SS and Girardi, G and Vega-Ostertag, M and Liu, X and Espinola, RG and Salmon, J. (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia Arthritis Rheum, pp. 2120-2124.
127. Marzari, R and Sblattero, D and Macor, P and Fischetti, F and Gennaro, R and Marks, JD and Bradbury, A and Tedesco, F. (2002) The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: In vitro and in vivo studies Eur J Immunol, 32, pp. 2773-2782.
128. Thurman, JM and Kraus, DM and Girardi, G and Hourcade, D and Kang, HJ and Royer, PA and Mitchell, LM and Giclas, PC and Salmon, J and Gilkeson, G and Holers, VM. (2005) A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice Mol Immunol, 42, pp. 87-97.
129. Vlaicu, R and Niculescu, F and Rus, HG and Cristea, A. (1985) Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque Atherosclerosis, 57, pp. 163-177.
130. Niculescu, F and Hugo, F and Rus, HG and Vlaicu, R and Bhakdi, S. (1987) Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries Clin Exp Immunol, 69, pp. 477-483.
131. Bhakdi, S and Dorweiler, B and Kirchmann, R and Torzewski, J and Weise, E and Tranum-Jensen, J and Walev, I and Wieland, E. (1995) On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety J Exp Med, 182, pp. 1959-1971.
132. Torzewski, M and Klouche, M and Hock, J and Messner, M and Dorweiler, B and Torzewski, J and Gabbert, HE and Bhakdi, S. (1998) Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion Arterioscler Thromb Vasc Biol, 18, pp. 369-378.
133. Rus, HG and Niculescu, F and Constantinescu, E and Cristea, A and Vlaicu, R. (1986) Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque Atherosclerosis, 61, pp. 35-42.
134. Seifert, PS and Hugo, F and Hansson, GK and Bhakdi, S. (1989) Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits Lab Invest, 60, pp. 747-754.
135. Torzewski, J and Torzewski, M and Bowyer, DE and Frohlich, M and Koenig, W and Waltenberger, J and Fitzsimmons, C and Hombach, V. (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries Arterioscler Thromb Vasc Biol, 18, pp. 1386-1392.
136. Lopes-Virella, MF and Virella, G. (1994) Atherosclerosis and autoimmunity Clin Immunol Immunopathol, 73, pp. 155-167.
137. Binder, CJ and Chang, MK and Shaw, PX and Miller, YI and Hartvigsen, K and Dewan, A and Witztum, JL. (2002) Innate and acquired immunity in atherogenesis Nat Med, 8, pp. 1218-1226.
138. Mayr, M and Metzler, B and Kiechl, S and Willeit, J and Schett, G and Xu, Q and Wick, G. (1999) Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis Circulation, 99, pp. 1560-1566.
139. Schett, G and Xu, Q and Amberger, A and Van der Zee, R and Recheis, H and Willeit, J and Wick, G. (1995) Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity J Clin Invest, 96, pp. 2569-2577.
140. Wieland, E and Dorweiler, B and Bonitz, U and Lieser, S and Walev, I and Bhakdi, S. (1999) Complement activation by oxidatively modified low-density lipoproteins Eur J Clin Invest, 29, pp. 835-841.
141. Seifert, PS and Hugo, F and Tranum-Jensen, J and Zahringer, U and Muhly, M and Bhakdi, S. (1990) Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions J Exp Med, 172, pp. 547-557.
142. Hamilton, KK and Sims, PJ. (1991) The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells J Clin Invest, 88, pp. 1833-1840.
143. Geertinger, P and Sorensen, H. (1977) On the reduced atherogenic effects of cholesterol feeding on rabbits with congenital complement (C6) deficiency Artery, 1, pp. 177-184.
144. Schmiedt, W and Kinscherf, R and Deigner, HP and Kamencic, H and Nauen, O and Kilo, J and Oelert, H and Metz, J and Bhakdi, S. (1998) Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits Arterioscler Thromb Vasc Biol, 18, pp. 1790-1795.
145. Patel, S and Thelander, EM and Hernandez, M and Montenegro, J and Hassing, H and Burton, C and Mundt, S and Hermanowski-Vosatka, A and Wright, SD and Chao, YS and Detmers, PA. (2001) ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5 Biochem Biophys Res Commun, 286, pp. 164-170.
146. Persson, L and Boren, J and Robertson, AK and Wallenius, V and Hansson, GK and Pekna, M. (2004) Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice Arterioscler Thromb Vasc Biol, 24, pp. 1062-1067.
147. Claudy, A. (1998) Pathogenesis of leukocytoclastic vasculitis Eur J Dermatol, 8, pp. 75-79.
148. Boom, BW and Mommaas, AM and Daha, MR and Vermeer, BJ. (1991) Decreased expression of decay-accelerating factor on endothelial cells of immune complex-mediated vasculitic skin lesions J Dermatol Sci, 2, pp. 308-315.
149. Dauchel, H and Joly, P and Delpech, A and Thomine, E and Sauger, F and Le Loet, X and Lauret, P and Tron, F and Fontaine, M and Ripoche, J. (1993) Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers Clin Exp Immunol, 92, pp. 274-283.
150. Kawana, S and Shen, GH and Kobayashi, Y and Nishiyama, S. (1990) Membrane attack complex of complement in Henoch-Schonlein purpura skin and nephritis Arch Dermatol Res, 282, pp. 183-187.
151. Boom, BW and Mommaas, M and Daha, MR and Vermeer, BJ. (1989) Complement-mediated endothelial cell damage in immune complex vasculitis of the skin: Ultrastructural localization of the membrane attack complex J Invest Dermatol, 93, pp. 68S-72S.
152. Leung, DY and Collins, T and Lapierre, LA and Geha, RS and Pober, JS. (1986) Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon J Clin Invest, 77, pp. 1428-1435.
153. Fujieda, M and Oishi, N and Kurashige, T. (1997) Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment Clin Exp Immunol, 107, pp. 120-126.
154. Ronco, P and Verroust, P and Mignon, F and Kourilsky, O and Vanhille, P and Meyrier, A and Mery, JP and Morel-Maroger, L. (1983) Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: A report of 43 patients with 51 renal biopsies Q J Med, 52, pp. 212-223.
155. Holmen, C and Christensson, M and Pettersson, E and Bratt, J and Stjarne, P and Karrar, A and Sumitran-Holgersson, S. (2004) Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies Kidney Int, 66, pp. 1049-1060.
156. Tripathy, NK and Upadhyaya, S and Sinha, N and Nityanand, S. (2001) Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu's arteritis J Rheumatol, 28, pp. 805-808.
157. Gabrielli, A and Zhang, ZX and Cherubini, G and Candela, M and Savoldi, S and Manzin, A and Clementi, M and Amoroso, A and Sallberg, M. (1996) Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia Clin Exp Immunol, 105, pp. 59-64.
158. Franklin, EC. (1980) The role of cryoglobulins and immune complexes in vasculitis J Allergy Clin Immunol, 66, pp. 269-273.
159. Kaplanski, G and Maisonobe, T and Marin, V and Gres, S and Robitail, S and Farnarier, C and Harle, JR and Piette, JC and Cacoub, P. (2005) Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia J Hepatol, 42, pp. 334-340.
160. Trendelenburg, M and Fossati-Jimack, L and Cortes-Hernandez, J and Turnberg, D and Lewis, M and Izui, S and Cook, HT and Botto, M. (2005) The role of complement in cryoglobulin-induced immune complex glomerulonephritis J Immunol, 175, pp. 6909-6914.
161. Werder, M and Truniger, B. (1997) Hypocomplementaemic urticarial vasculitis Nephrol Dial Transplant, 12, pp. 1278-1279.
162. Trendelenburg, M and Courvoisier, S and Spath, PJ and Moll, S and Mihatsch, M and Itin, P and Schifferli, JA. (1999) Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus? Am J Kidney Dis, 34, pp. 745-751.
163. Wisnieski, JJ and Jones, SM. (1992) Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus J Immunol, 148, pp. 1396-1403.